Log In | Shopping Cart | Advanced Search
            
  • Home
  • Career
  • Distributors
  • Contact Us:
  • Email: crm@excellgen.com
Products
Modified mRNA
Encapsulated mRNA
mRNA Enzyme
SARS-CoV-2
Pseudovirus
Popular Products
Cancer Proteins
Antibodies
DNA Binding Proteins
Electrophoresis
Genome Engineering
Polymerases
Recombinases
Transcription Factors
Transfection
Comsumbles
Services
Modified mRNA
Custom Cloning
Virus Production
Protein Purification
Protein Expression
Antibodies
 Previous 
 Return to List 
 Next 

Anti-LAG3 monoclonal antibody, recombinant

Catalog #: EG-374


$250.00

Qty:

EG-374 Anti-LAG3-M36
Product Name Anti-LAG3 monoclonal antibody, recombinant
Cat # EG-374
Size 100 µg
Key features Rabbit monoclonal antibody produced in 293 cells with serum-free, protein-free medium, purified with protein A column;
High batch-to-batch consistency and reproducibility;
Long term security of supply;
Clone number M36
Immunogen Recombinant extracellular domain of LAG3 that was expressed and purified from 293 cells
Reaction target Extracellular region of LAG3
Species Cross-Reactivity Human
Applications Flow Cytometry; IP; ELISA;
Working concentrations Flow cytometry and ELISA: 5 µg/ml of final concentration is suggested.
IP: 10 μg in 0.3-0.5 mg cell lysates is suggested.
Background LAG3 (CD223) is a new type of immune check point protein expressed on activated T cells. LAG3 upregulation is required to control overt activation of T cells and prevent the onset of autoimmunity (1). Persistent antigen stimulation results in sustained LAG3 expression, leading to T cell exhaustion. Currently, LAG3 neutralizing antibodies alone or in combination with PD-1/PD-L1 blockade are being rigorously explored as potent immunotherapy strategy to treat solid cancers in clinical trials. Several LAG3 ligands have been proposed, including MHC II, FGL-1, and Galectin-3. Cell surface LAG3 may be cleaved by ADAM10/17 metalloproteinases and released into the blood stream (1). M36 antibody weakly blocks the binding of recombinant LAG3 to MHC II-expressing Raji cells at high concentration.
References: (1) Lawrence P Andrews, et al. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 2017; 276:80-96.
QC

A) Flow cytometry analysis of cell surface expression of LAG3. Peripheral blood mononuclear cells (PBMC) were activated in vitro with anti-CD3/anti-CD28 beads. Cell surface expression of LAG3 of activated PBMC was detected with the antibody. Activated PBMC (10^6) were incubated with 5 μg antibody in 1 ml PBS buffer containing 5% BSA. Antibody binding was detected with Cy5-conjugated goat-anti-rabbit antibody. Shaded area, isotype control antibody staining; red line, PBMC activated for 1 day; Green line, PBMC activated for 3 days; Blue line, PBMC activated for 7 days. 
B) Blocking activity of LAG3 monoclonal antibody M36. Recombinant extracellular domain of LAG3 (LAG3ECD-hFc) was shown binding to Raji cells at 10 μg/ml. M36 does not block the binding of LAG3 to Raji cells at 1 and 5 μg/ml, partially blocks at higher concentration of 20 μg/ml.

Concentration As indicated on the vials
Formulation 80% PBS, pH 7.4; 20% Glycerol; 5% Trehalose; 0.04% Sodium azide as Preservative
Shipping Blue ice
Storage -20 to -70 oC (long term) or 4 oC (one week).
Depending on the expected frequency of use, the product can be aliquoted to avoid heavily repeated freezing/thawing cycles.

     
 Ask a Question 
 
 Home | Privacy Policy | Terms & Conditions | Online Price Policy | Shipping & Return

Copyright © 2007-2023  Excellgen, Inc. All rights reserved